To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Jason M. Broderick
The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
Gary Stromberg
After extensive chemo treatment was completed, intended to kill all the leukemic cells in my sick body, a courier was sent to Israel to collect the harvested marrow from my donor, and immediately fly it back to the U.S. where I was to be infused.
Brielle Urciuoli
The potential approval offers hope to the rare blood cancer, which currently has no standard of care treatment protocol.
Blincyto (blinatumomab) was granted approval by the Food and Drug Administration (FDA) to treat patients who have B-cell precursor acute lymphoblastic leukemia (ALL), who are in remission but still have minimal residual disease (MRD).
Jason M. Broderick
Tasigna (nilotinib) was granted Food and Drug Administration (FDA) approval, to be used in the first- and second-line setting for pediatric patients 1 year old or older who have Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). 
Jane N. Winter, M.D.
The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.
Brian Koffman, MDCM, MSEd, provides insight from a patient’s perspective on self-advocacy and reflects on the positive direction in which the treatment paradigm of chronic lymphocytic leukemia (CLL) is heading.
Brian Koffman, MDCM, MSEd, describes the inspiration he had to form the nonprofit CLL Society and outlines the resources it provides for any patient with chronic lymphocytic leukemia (CLL).
Brian Koffman, MDCM, MSEd, shares insight on his current relapse of chronic lymphocytic leukemia (CLL) and discusses the potential value of chimeric antigen receptor (CAR) T-cell therapy, which he will be receiving in an upcoming clinical trial.
Brian Koffman, MDCM, MSEd, discusses his rejection of allogeneic stem cell transplant and development of chemorefractory chronic lymphocytic leukemia (CLL) that led to his participation in an early clinical trial of ibrutinib.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other